Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Atazanavir and Cobicistat Mini-tablets in Healthy Adults
NCT05236738Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atazanavir and cobicistat in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 17 days and Area under the plasma concentration-time curve from time zero extrapolated to infinite time up to 17 days. Started May 2022; status: completed.
02
Drugs
atazanavircobicistat
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05236738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05236738.